Hepatic NAD⁺ deficiency as a therapeutic target for non‐alcoholic fatty liver disease in ageing

Abstract

These results provide the first evidence that ageing-associated NAD(+) deficiency is a critical risk factor for NAFLD, and suggest that supplementation with NAD(+) substrates may be a promising therapeutic strategy to prevent and treat NAFLD.